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Abstract
The role of extracellular vesicles (EVs) as vehicles for cell-to-cell communication between a tumour and its environment is a
relatively new concept. The hypothesis that EVs may be critical in co-opting tissues by tumours to generate distant
metastatic niches is particularly pertinent to prostate cancer (PCa), where metastatic-tropism to bone predominates over other
tissue types. The potential role of EVs as a means of communication between PCa cells and cells of the bone stroma such as
osteoblasts, is yet to be fully explored. In this study, we demonstrate that PCa cell EVs both enhance osteoblast viability and
produce a signiﬁcantly more supportive growth environment for PCa cells when grown in co-culture with EV-treated
osteoblasts (p < 0.005). Characterisation of the RNA cargo of EVs produced by the bone-metastatic PCa cell line PC3,
highlights the EV-RNA cargo is signiﬁcantly enriched in genes relating to cell surface signalling, cell–cell interaction, and
protein translation (p < 0.01). Using novel techniques to track RNA, we demonstrate the delivery of a set of PCa-RNAs to
osteoblast via PCa-EVs and show the effect on osteoblast endogenous transcript abundance. Taken together, by using proof-
of-concept studies we demonstrate for the ﬁrst time the contribution of the RNA element of the PCa EV cargo, providing
evidence to support PCa EV communication via RNA molecules as a potential novel route to mediate bone metastasis. We
propose targeting PCa EVs could offer a potentially important preventative therapy for men at risk of metastatic PCa.
Introduction
Prostate cancer is the second leading cause of cancer-related
death in men and the most commonly diagnosed male
malignancy worldwide, with > 1.1 million cases recorded in
2012, which accounts for 15% of all new cancer cases in
men [1]. In advanced PCa, 80% of men will have cancer
that has metastasised to bone. At this stage, treatment
options focus on palliative care and the 5-year survival rate
for these patients is ~ 30% [2]. Why and how bone becomes
the focus of PCa remains uncertain. In this study, we
explore the RNA cargos of extracellular vesicles (EVs)
secreted by PCa cells, to determine their effect on bone
osteoblasts as a potential means of inﬂuencing PCa bone
metastasis.
The concept of tumour-secreted factors, such as EVs, as
a means of communication within the metastatic process is
relatively new, but recent studies provide compelling evi-
dence for further investigation [3–14]. For example, studies
of TLR3−/− knockout mice found the RNA cargo of mel-
anoma EVs was capable of activating signalling pathways
in lung epithelial cells, resulting in chemokine secretion and
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spontaneous lung metastasis, strongly supporting a role for
cancer cell EVs in the metastatic process [9].
EVs are any type of lipid bilayer bound vesicle released
into the extracellular space. Typically, EVs are classiﬁed
based on their biogenesis and size, but they also differ in
their molecular content, membrane composition, and spe-
ciﬁc functions. Classiﬁcation by biogenesis and size depicts
three core types of EV, exosomes that are the smallest in
size and form from inward budding of the endosomal
membrane (30–150 nm), and are thought to have a func-
tional role in cell–cell communication [15, 16]. Micro-
vesicles form from outward budding of the plasma
membrane (> 50–1000 nm) and have classically been
thought of as a means of evacuating waste/unwanted pro-
ducts from the cell [17, 18]. Finally, apoptotic bodies (50
nm–5 µm) are formed through the disassembly of other
membrane-bound vesicles and released in the later stages of
apoptosis [16]. EVs are known to carry a cargo of proteins
and genetic material, of which a large variety of RNA
species are found to be present including messenger RNAs
(mRNA), microRNAs (miRNAs), transfer RNAs (tRNAs),
small nucleolar RNAs (snoRNAs), small nuclear RNAs
(snRNAs), mitochondrial-associated RNA, Piwi-interacting
RNAs (piRNAs), vault RNAs, Y-RNAs, ribosomal RNAs,
and long non-coding RNAs [19–24]. Identiﬁcation of
miRNAs in PCa vesicles, within the population classiﬁed as
exosomes, has yielded some potential new prognostic
markers [25–29], but the potential function of these EV-
RNAs is yet to be determined.
In this study, we use in vitro models and novel RNA-
tracking techniques to explore the RNA cargos of PCa EVs,
which fall within the category of exosomes, to investigate
the interaction between PCa cells and osteoblasts. Demon-
strating a method of communication that has the potential to
mediate PCa to bone metastasis.
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Results
PCa EVs increase osteoblast viability creating an
enhanced growth environment in vitro
To investigate if PCa EVs have the potential to affect cell
types which may reside within a potential bone-metastatic
niche, we ﬁrst sought to determine whether EVs isolated
from PCa cells PC3 (which has a propensity to metastasis to
bone in vivo) C4-2, (which shows occasional metastasise to
bone in vivo [30]), and C4-2-4B (a bone-metastatic lineage
of C4-2 [30]) could induce a change in osteoblast viability.
An immortalised osteoblast cell line (hOB) was exposed to
one dose of EVs isolated from PC3, C4-2, C4-2-4B PCa
cells or PNT1A (a non-malignant immortalised prostate
epithelial cell line) or a separate population of hOB cells,
treatment with media containing no EVs was used as a
negative control. EVs were characterised as being within
the category of exosomes as determined by Brownian
motion (Zetaview, ParticleMetrix) and immunoblot analysis
(Supplementary Figures 1 and 2). Treatment with all PCa
EVs (PC3, C4-2, C4-2-4B) resulted in a signiﬁcant increase
in hOB viability 24 h after treatment (p= 0.004, p= 0.032,
p= 0.0001 respectively) (Fig. 1a). Similar results were
found when using a second osteoblast cell line hFOb1.19
(Supplementary Figure 3).
To determine whether the changes in osteoblast viability,
induced by PCa EVs, result in a supportive growth envir-
onment for subsequently arriving PCa cells (as a
rudimentary model of early metastasis). Osteoblasts (hOBs)
were incubated with EVs isolated from PC3, C4-2 or the
non-PCa cell line Hek293 for 24 h, prior to the addition of
PCa cells to form a co-culture system (illustrated in Fig. 1b).
The number of the co-cultured PCa cells was measured over
48 h. The co-culture of PC3 cells, with hOB cells that had
been pre-treated with PC3-derived EVs, resulted in a sig-
niﬁcant increase in PC3 cell number when compared with
PC3 cells co-cultured with hOB cells pre-treated with EVs
isolated from the non-prostate HEK293 cells (12 h p=
0.0015; 24 and 48 h p < 0.0001), or no pre-treatment (12 h
p= 0.0004; 24 and 48 h p < 0.0001) (Fig. 1c). The growth
of C4-2 cells within the co-culture system was similarly
inﬂuenced by pre-treatment of hOB cells with C4-2-derived
EVs (compared with no treatment 12, 24 and 48 h p=
0.0004, and Hek293 EVs 12, 24 and 48 h p < 0.0001) (Fig.
1d).
Taken together, these data indicate PCa EVs alter hOB
viability. Moreover, the EV-mediated changes that result
from pre-treatment of hOB cells result in increased titres of
later arriving PCa cells, an effect not replicated by EVs of
non-prostate cell types. Therefore, demonstrating PCa EVs
deliver a pro-tumour cell signal. As we demonstrated PCa
EVs were able to affect the viability of osteoblasts, a major
cell type affected in PCa bone metastasis, we choose to
determine the role of the EV cargo. As other studies have
identiﬁed some protein components of cancer EV cargos,
we choose to ascertain the potential contribution of the
RNA cargo of PCa EVs.
Characterisation of PCa EV-miRNA
To further explore the RNA cargo of PCa EVs, RNAseq
was used to identify the miRNA and mRNA cargo of EVs
isolated from the bone-metastatic PC3 PCa cell line.
Sequencing reads were mapped using miRBase to identify
miRNAs and to allow a comparison to the previous study of
the miRNA content of PC3 exosomes [31] (the only full
data set publically available GSE35813 at the time of
study). A comparison of the two studies identiﬁed 40.3% of
the miRNAs identiﬁed in our study were also reported by
Hessvik et al. [31] (Fig. 2a). When comparing this with
reports of miRNAs with prognostic signiﬁcance (associated
with progression to metastasis and/or detection of high/
intermediate risk PCa) detected in EVs isolated from PCa
patient plasma and urine, 76.5% of the these miRNAs were
identiﬁed in our study compared with 47.1% in the Hessvik
et al. study [25–27, 29, 31] (Fig. 2a) (details of the in
common miRNAs are reported in Supplementary Table 1).
Variations in the miRNA cargos of vesicles may be a
representation of the biological heterogeneity of EVs and
the inﬂuence of different stimuli encountered during the
culture process [32]. An additional source of differences
Fig. 1 Extracellular vesicles isolated from prostate cancer cells with a
bone-metastatic propensity educate osteoblasts to create an enhanced
growth environment. a Osteoblasts (hOBs) were treated with extra-
cellular vesicles (EVs) isolated from cultured prostate cancer cell lines
PC3, C4-2, C42-B, PNT1A, the same hOB cell line or no EV control,
cell viability was measured after 24 h using an MT luciferase assay. A
signiﬁcant increase in luciferase was detected in hOB cells treated with
EVs from prostate cancer cell lines PC3, C4-2 and C42-4B (p= 0.004,
p= 0.032, p= 0.0001, respectively) (n= 3). b To determine whether
the exposure of osteoblasts to EVs creates and environment supportive
of prostate cancer cell growth, osteoblasts (hOBs) were pre-treated by
incubating cells for 24 h with extracellular vesicles (EVs) isolated from
cultured prostate cancer cell lines PC3 and C4-2, HEK-293 as a non-
cancer control, or with PBS only. After 24-hours, hOBs were washed
in PBS and co-cultured with the same prostate cancer cell line used to
isolate the EVs (during co-culturing the prostate cancer cells were
grown on cell culture inserts to prevent cell-to-cell contact. Cell
number was measured at 12, 24 and 48 h (in triplicate) and changes in
growth rates compared across the different EV treatments. c Pre-
treatment of hOBs with PC3-EVs for 24 h as described above, resulted
in a signiﬁcant increase in PC3 cell number during co-incubation
across all time points, compared with hOBs incubated with non-cancer
HEK-293 EVs or PBS. d As seen in c, pre-treatment with C4-2 EVs as
described above, resulted in a signiﬁcant increase in cell number
compared to HEK-293 EVs and PBS alone. a, c, d P values deter-
mined using a two-way ANOVA and Bonferroni’s multiple compar-
ison test b P values determined using one-way ANOVA and Holms-
Sidak correction, error bars represent standard deviation n= 3. *p ≤
0.05, **p ≤ 0.01, ***p ≤ 0.001, ns not signiﬁcant
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may also occur through the process of isolating vesicles via
size exclusion and ultracentrifugation techniques, as well as
the use of RNAseq versus array-based technologies to
proﬁle the miRNAs [33]. However, these comparisons
demonstrate a core of miRNAs can be detected in PCa EVs
across studies.
Fig. 2 Analysis of the potential function of PC3 EV-miRNAs and a
comparison of mapped microRNA between publically available stu-
dies of the PC3 cell line and prostate cancer patient urine and plasma
EVs. Data from our study (Probert 2017), Hessvik et al., a similar
study of PC3-EVs [31] and published ﬁndings of miRNAs with
prognostic relevance identiﬁed in EVs isolated from patient urine and
plasma [25–27, 29] were mapped to miRBase to create a data set for
the comparative analysis described a–d. a Venn diagram to show
microRNAs shared between the studies. In all, 40.3% of miRNAs
identiﬁed in our study were also reported to be present in PC3 cell line
isolated EVs studied by Hessvik et al. [31]. In comparison, 76.5% of
miRNAs detected in urine and plasma EVs isolated from patients and
reported to have prognostic potential, were also present in our study. b
Venn diagram to show the mRNA targets of the EV-miRNA cargos
across the described studies [25–27, 29, 31]. c Comparative cellular
component analysis of the mapped microRNAs across the studies
demonstrate similar percentages of target genes in the same cellular
compartments irrespective of the study/origin of the EVs (cell line or
patient sample origin). d The same is the case when comparative
biological pathway analysis is applied. The characterised major bio-
logical pathways potentially targeted by the EV-miRNA cargos
represent cell surface/membrane signalling and interaction mechan-
isms. Venn diagrams and comparative analysis conducted using
FUNRICH V3 [45]
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In addition to identifying the miRNA types, determining
the targets of those miRNAs demonstrates that between our
study of PC3-EVs and Hessvik et al., 82.1% and 96.6% of
predicted gene targets are shared, respectively (Fig. 2b).
Extending the comparison of miRNA gene targets with the
studies of patient plasma and urine, 94.98% of genes
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targeted by the miRNAs in those studies are in common
with our study (Fig. 2b). These data indicate an overlap in
genes targeted by EV-miRNAs despite some difference in
the miRNA composition of those EVs, this is further sup-
ported by comparative cell component and biological
pathway analysis. Cell component analysis identiﬁed a
signiﬁcant enrichment of genes within different cell com-
partments, targeted by the all miRNAs identiﬁed in our
study and all miRNAs identiﬁed in the studies used in the
previous comparison [25–27, 29, 31]. The top ﬁve cell
compartments showing enrichment of gene targets were as
follows nucleus (p < 0.01), cytoplasm (p < 0.01), plasma
membrane (p < 0.01), exosomes (p < 0.01 except for studies
of urine and plasma EVs), and lysosomes (p < 0.01) (Fig.
2c). All studies showed a similar percentage of target genes
across these ﬁve components. This is further exempliﬁed
through comparative biological pathway analysis, the top
ﬁve pathways showing a signiﬁcant enrichment of target
genes were Integrin family cell surface interactions, Gly-
pican pathway, Proteoglycan syndecan-mediated signalling
events, Beta1 integrin cell surface interactions, and TRAIL
signalling (all p < 0.01) (Fig. 2d). All ﬁve pathways
correspond to cell surface signalling and cell interaction
mechanisms.
Following the characterisation of the miRNA cargo,
labelling of nascent RNA with 5-Ethynyl Uridine (5EU) in
PC3, non-malignant PNT1A and hOB cells was used to
track RNA originated from EVs, to determine whether
miRNAs transferred from PC3-EVs could be detected in
recipient osteoblasts.
Afﬁnity capture was used to isolate the 5EU-labelled
RNA present in EV-recipient hOB cells, and the captured
5EU RNA was subsequently probed for the presence of
miR21 by qPCR (Fig. 3a). MiR21 was chosen for our study
as its transfer between ovarian stromal cell types has pre-
viously been demonstrated [34]. Moreover, miR21 is
known to be expressed in our cell lines and has been
identiﬁed as a prognostic factor in the urine and plasma of
PCa patients [27, 29]. Labelled 5EU-miR21 was detected in
hOB cells following exposure to EVs isolated from all 5EU-
treated cell lines (PC3, PNT1A and hOB) (p < 0.001 when
compared with a background control), with the greatest
abundance detected following treatment with PC3-EVs
(Fig. 3b). To determine the potential functional effect of
EV-miRNAs, PC3 cells were transfected with either a
miR21 mimic to increase miR21 levels or an siRNA to
deplete pre-miR21 hairpins to decrease the abundance of
mature miR21 within the cells prior to the isolation of EVs,
or a non-targeting small RNA control (si-control) (Fig. 3c).
The abundance of miR21 was quantiﬁed in the isolated
PC3-EVs (Fig. 3d), and the EVs subsequently applied to
hOB cells transfected with a luciferase reporter containing
miR21-binding sites within the 3’UTR. Luciferase levels
were determined 24 h after treatment with EVs. Exposure of
hOB cells to PC3-EVs depleted of mature miR21 (si-miR21
EVs) resulted in a signiﬁcant increase in luciferase trans-
lation (p= 0.00002) (Fig. 3e). Furthermore, exposure of
hOBs to miR21-depleted PC3-EVs resulted in a reduction
in cell viability (p= 0.013) (Fig. 3f).
To determine the effect of PCa miRNAs on osteoblasts
more generally, the miRNA biogenesis pathway of PCa
PC3 cells was abrogated using Dicer RNAi (Supplementary
Figure 4). Osteoblasts treated with EVs isolated from Dicer-
depleted PC3 cells resulted in a signiﬁcant reduction in
osteoblast number (p < 0.0001) (Fig. 3g, h), indicating an
RNA-dependent effect on osteoblast viability.
Using miR21 as an example, we have been able to
conﬁrm the transfer of PCa cell-derived miR21 transcripts
to osteoblasts via PCa EVs. Furthermore, depleting the
mature miR21 content of the PCa EVs results in loss of
miR21-speciﬁc miRNA-mediated translational repression.
This ﬁnding is in keeping with the work of Sanchez et al.,
(2016), who identiﬁed miR21 together with miR100 as the
most abundant vesicle miRNAs in PCa. Furthermore, the
authors found miR21 contributes to pre-metastatic niche
Fig. 3 Detection of labelled microRNA-21 (miR21) originating from
bone-metastatic prostate cancer cell lines in recipient osteoblasts and
functional effects of EV-miRNAs. a–b PNT1A (normal prostate), PC3
(prostate cancer) or hOB (osteoblast) cells were grown in the presence
of 5EU to label nascent RNA transcripts. Post-labelling EVs produced
from these cell lines were isolated and applied to hOBs cells grown
under standard conditions (no EU label). After 48 h, the EV-treated
hOB cells were lysed and the total RNA extracted, from the pool of
total RNA 5EU-labelled RNA was precipitated and the presence of
labelled miR21 determined by qPCR. c Quantiﬁcation of mature
miR21 abundance in PC3 cells 48 hours post transfection with siRNAs
targeting miR21 hairpins, miR21 mimics or a non-targeting siRNA
control (n= 3). d Quantiﬁcation of mature miR21 abundance in EVs
isolated from PC3 cells 48 hours post transfection with siRNAs tar-
geting miR21 hairpins, miR21 mimics or a non-targeting siRNA
control (n= 3). e To determine whether the EV-miR21 can elicit a
functional response, psiCHECK2 luciferase reporter assays containing
miR21-binding sites were transfected into osteoblasts 48 h prior to
treatment with EVs isolated from PC3 cells. Treatment with PC3-EVs,
modiﬁed to deplete miR21 from the EV cargo, resulted in a signiﬁcant
increase in the expression of the luciferase reporter (p= 0.00002) (n=
3). f Exposure of hOB cells to miR21-depleted PC3-EVs also results in
a reduction in hOB cell viability (p= 0.0134). g–h To determine the
potential contribution of RNAs to the modiﬁcation of the osteoblast
phenotype by EVs, PC3 cells were transfected with siRNA against
dicer (si-dicer) or a non-targeting siRNA (si-scr) control (Supple-
mentary Figure 4). After 48 h post of transfection EVs were isolated
from the PC3 cells and transferred to hOB (osteoblast) cells growing
under normal conditions. The cell titre of hOB cells was determined
24 h after treatment with EVs isolated from PC3 cells treated with
either si-scr or si-dicer (n= 3 biological replicates). h Treatment with
EVs isolated from si-dicer-treated PC3 cells resulted in a signiﬁcant
reduction in hOB cell titre (p < 0.0001), indicating the involvement of
miRNAs and/or the biogenesis pathway in altering the behaviour of
EV-recipient cells. t test with Holm–Sidak correction error bars
represent standard deviation n= 3. *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001
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preparation when introduced to stromal cells [35]. Although
we cannot conﬁrm if these data are unique to miR21, this
ﬁnding together with the effect of Dicer-depletion on
osteoblast number (Fig. 3g) support a functional role for
PCa EV-miRNAs.
Characterisation of PCa EV-mRNA
In addition to miRNAs, 572 mRNA transcripts were iden-
tiﬁed by RNAseq analysis of PC3-EVs. Exploration of the
potential functions of this population by cellular
compartment analysis indicates an enrichment of genes
involved in both nuclear and cytoplasmic functions (Fig.
4a). Perhaps more informative, biological pathway analysis
shows a predominance of genes involved in protein trans-
lation, the top 10 pathways are illustrated in Fig. 4b (full list
detailed in Supplementary Table 2).
Similar to the study of EV-miRNAs, we sought to
determine whether the mRNA cargo of PCa EVs could also
be detected in the recipient osteoblasts (Fig. 5a). We ana-
lysed the abundance of ﬁve genes that, based on our
RNAseq data, were known to be expressed in the EVs of
Fig. 4 Analysis of messenger RNA (mRNA) transcripts present in
PC3-EVs identiﬁes an enrichment of genes involved in polymerase III
transcription. a Cell component analysis demonstrates a signiﬁcant
enrichment of genes involved in nuclear functions (Nucleus, Nucleolus
and Centrosome) and cytoplasmic functions involved in translation
(ribosomes) and endosomal vesicle formation (exosomes). b Biologi-
cal pathway analysis indicates a signiﬁcant enrichment of process
involved in protein translation (top 10 shown, full analysis detailed in
Supplementary Table 2)
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PCa cell lines (Supplementary Figure 5). Furthermore, this
subset of genes have key roles in osteoblast function and
consist of colony-stimulating factor 1 (CSF-1) a factor
present on the osteoblast cell surface and secreted by
osteoblasts to mediate osteoclast formation [36], Ephrin A3
(EFNA3) required for osteoblast cell–cell interaction and
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osteoblastic bone formation [37], vascular endothelial
growth factor A (VEGFA) osteoblasts are stimulated to
produce VEGFA in response to bone morphogenetic pro-
teins to couple angiogenesis and bone formation processes
[38], C–C motif chemokine ligand 2 (MCP1) produced by
osteoblasts and hypothesised to be involved in the recruit-
ment of osteoclast precursors and an activator of NF-
KappaB ligand induced osteoclastogenesis [39], Runt-
related transcription factor 2 (RUNX2) the constitutive
expression of which is required to maintain the mature
osteoblast phenotype [40], and ﬁbroblast growth factor 2
(FGF2) expressed by osteoblasts and an important regulator
of bone formation [41].
Osteoblasts were treated with EVs isolated from 5EU-
labelled cells and the abundance of detectable 5EU-labelled
mRNA transcripts within the treated hOB cells determined
by qPCR (Fig. 5a, b). When compared with hOBs treated
with EVs isolated from 5EU-labelled normal prostate epi-
thelial cells (PNT1A), treatment with PC3-EVs resulted in a
signiﬁcant increase in 5EU-labelled RNAs transcripts for
CSF-1 (p= 0.033), VEGFA (p= 0.013), MCP1 (p=
0.009), RUNX2 (p= 0.016) and FGF2 (p= 0.028) (Fig.
5b). Similarly, treatment with PCa C4-2 and C42-B4 EVs,
resulted in detection of increased 5EU-labelled CSF-1,
MCP1 and RUNX2, but not VEGFA or FGF2 as seen with
PC3. (p= 0.001, p= 0.001, p= 0.001 and p < 0.0001, p=
0.001, p= 0.002, respectively). In the case of EFNA3,
5EU-labelled transcripts were not detected following treat-
ment with PC3 or hOB EVs, but were detected after
exposure to EVs from the less bone-metastatic C4-2 cell
line (Fig. 5b). Treatment of osteoblasts (hOB cells) with
EVs isolated from a separate population of 5EU-labelled
hOB cells, also resulted in the detection of labelled CSF-1,
VEGFA, MCP1, RUNX2 and FGF2 transcripts within the
EV-recipient hOB cells (Fig. 5b).
As equal doses of EVs (based on total protein and EV
characterisation) were applied to osteoblasts, differences in
the osteoblast-transferred RNA cargos between EVs origi-
nating from different cell types suggest PCa EV-RNA
cargos are likely tailored to promote changes in osteoblasts
and/or other cells of the tumour microenvironment that
would be beneﬁcial to the tumour, as seen in the previous
co-culture assays (Fig. 1c, d). For example, EFNA3 mRNA
transcripts, whereas a detectable component of the PC3 EV
cargo, appear not to be transferred at high abundance by
EVs resulting from either bone-metastatic cell lines PC3
and C4-2-4B, but are transferred by C4-2, Further support
for the presence of highly tailored PCa EV-RNA cargos is
provided by our comparative analysis, which determined a
signiﬁcant enrichment of genes involved in key gene
expression pathways (Fig. 4). However, the changes pro-
moted by such cargos are yet to be modelled in vivo for
PCa.
The transfer of mRNAs by EVs raises the question of the
contribution they make to the overall transcriptome of the
recipient cell. Do they simply increase the overall abun-
dance or are they subject to regulation? By determining the
abundance of CSF-1, VEGFA, MCP1, Runx2 and FGF in
hOB cells exposed to PC3-EVs, we found the abundance of
CSF-1 was signiﬁcantly increased (p < 0.001). The level of
FGF2 was also increased albeit signiﬁcance was not
reached. There was no signiﬁcant change in the abundance
of VEGFA, MCP1 or Runx2 (Fig. 5c). Similar results were
found when using EVs isolated from PCa C4-2 cells
(Supplementary Figure 5). The lack of increased abundance
of MCP1, VEGFA and Runx2 was particularly marked, as
compared with CSF-1 the abundance of these transferred
mRNAs was between 4–6-fold higher (Fig. 5b). Therefore,
other mechanisms of regulation must be active to control
the overall levels of these transcripts within the osteoblast,
signifying the possibility that the recipient osteoblast is only
subject to the inﬂuence of a proportion of the RNAs present
within the EV. Although it highly likely the source of RNA
regulation is predominantly from the EV-recipient cell, we
Fig. 5 Detection of labelled mRNAs originating from bone-metastatic
prostate cancer cell lines in recipient osteoblasts and the contribution
to overall transcript abundance in recipient osteoblasts. a PNT1A
(normal prostate), PC3, C4-2, C4-2-4B (prostate cancer) or hOB
(osteoblast) cells were grown in the presence of 5EU to label nascent
RNA transcripts. Post-labelling EVs produced from these cell lines
were isolated and applied to hOBs cells grown under standard con-
ditions (no EU label). After 48 h, the EV-treated hOB cells were lysed
and the total RNA extracted, from the pool of total RNA EU-labelled
RNA was precipitated and the presence of labelled CSF-1, VEGFA,
MCP1, Runx2 and FGF2 quantiﬁed. b All EU-labelled transcripts
were detected at signiﬁcantly higher levels in hOB cells treated with
EVs isolated from EU-labelled PC3 cells compared with EU-labelled
PNT1A cells (CSF-1 p= 0.0395, VEGFA p= 0.0134, MCP1 p=
0.0086, Runx2 p= 0.0168, FGF2 p= 0.0284) (n= 3). Similar treat-
ment with prostate cancer C4-2 and C42-B4 EVs, resulted in detection
of increased 5EU-labelled CSF-1, MCP1 and RUNX2, but not
VEGFA or FGF2 as seen with PC3. (p= 0.001, p= 0.001, p= 0.001
and p < 0.0001, p= 0.001, p= 0.002, respectively) (n= 2). c Analysis
of total RNA extracted from hOBs after treatment with labelled PC3-
EVs in a demonstrated a signiﬁcant increase in abundance of CSF-1
and a smaller increase in FGF2 (similar results were obtained fol-
lowing treatment with C4-2 EVs Supplementary Figure 6). d To
determine how the miRNA element of the EV cargo may inﬂuence the
subsequent processing of the mRNA cargo component in the recipient
cell, PC3 cells were transfected with siRNA against dicer (si-dicer) or
a non-targeting siRNA (si-scr) control. 48 h post transfection EVs were
isolated from the PC3 cells and transferred to hOB (osteoblast) cells
growing under normal conditions. The abundance of VEGFA, MCP1
and Runx2, shown previously to have no altered abundance within the
osteoblast transcriptome a–b, were quantiﬁed. A signiﬁcant increase in
the expression of MCP1 (p<0.0001) was determined, but no change in
VEGFA and Runx2 could be detected (n= 3). Western blot con-
ﬁrmation of Dicer knockdown and controls for the siRNA loading into
EVs is included in Supplementary Figure 4. t test with Holm–Sidak
correction error bars represent standard deviation n= 3. *p ≤ 0.05,
**p ≤ 0.01, ***p ≤ 0.001
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identiﬁed that 3.5% of the mRNAs identiﬁed within PC3
vesicles by RNAseq are targets of the vesicle miRNA cargo
(Supplementary Figure 7). Therefore, we questioned if the
miRNA cargo of the EVs inﬂuences the overall expression
of MCP1, VEGFA and Runx2 in the recipient osteoblast.
Using EVs isolated from PC3 cells treated with Dicer
RNAi, we reanalysed the abundance of VEGFA, MCP1 and
Runx2, ﬁnding only a signiﬁcant increase in the abundance
of MCP1 (p < 0.0001) (Fig. 5d). Therefore, indicating EV-
miRNA-mediated negative regulation, whereas applicable
to MCP1, is not a general mechanism of regulating mRNAs
carried within the EV cargo.
The presence of mechanisms to regulate the EV cargo in
the recipient cell, to ﬁne tune the messages received and
responded too, may prove to be vital in advancing our
understanding of how PCa cells hijack the normal physio-
logical processes mediated by EVs in the bone (reviewed
ref. [42]), and importantly how therapeutic agents can be
targeted to disrupt only the non-physiological/cancer-spe-
ciﬁc processes mediated by EVs.
Discussion
The role of EVs as vehicles for cell-to-cell communication
between a tumour and its environment is a relatively new
concept, with only limited study of this potential mechan-
ism in PCa. Our data are the ﬁrst to demonstrate the transfer
of RNA molecules from PCa cells to recipient osteoblasts
and the importance of PCa EVs in changing osteoblast
behaviour to support PCa cell proliferation. These data are
in keeping with similar studies of melanoma EVs, where
EV-RNA cargos were associated with mediating sponta-
neous lung metastasis [9]. The characterisation of the RNA
content of PCa EV delineates the targeting of pathways
important for osteoblast function and interaction with the
surrounding microenvironment, both of which are in
keeping with the changes in osteoblast viability observed
following treatment with PCa cell EVs. Furthermore, we
provide evidence of the function of transferred miRNAs in
EV-recipient osteoblasts, and demonstrate the impact of
RNA regulation on the retention of EV-RNA molecules,
highlighting a mechanism potentially enabling the recipient
cell to select, which messages within the EV communica-
tion system to ‘listen’ too.
This proof-of-principle study provides the critical evi-
dence needed to warrant investigation of this complex inter-
cell communication system in the context of in vivo models
of PCa, particularly the potential of EVs to act in promoting
metastasis. We propose further investigation using in vivo
models are required to determine whether this form of
communication acts as an initial or late event within the
metastatic process. However, at the current time the tools
required to delineate the functional role of EV-RNAs within
a complex in vivo model of prostate bone metastasis are not
yet available. The techniques successfully used in this study
provided a basis for the development of future in vivo
reagents to track the biodistribution of EV-RNA cargos
combined with functional readouts of disease progression
such as the extent of metastasis. Overall, these data provide
an exciting step forwards in our understanding of how PCa
cells use the EV-RNA cargo to communicate with osteo-
blasts and highlights the potential importance of the EV-
RNA cargo as a mediator of PCa progression.
Materials and methods
Cell lines and culture conditions
PCa PC3, Hek293 and hfOb1.19 cells were obtained from
ECACC (Culture Collections, Salisbury, UK) and cultured
in Dulbecco’s modiﬁed medium (#D5796, Sigma, Dorset,
UK) supplemented with 10% fetal bovine serum (#B9433,
Sigma), 50 U ml−1 penicillin and 50 µg ml−1 streptomycin
(#15140122, Gibco, Loughborough, UK). C4-2 cells were
provided in collaboration by Dr Nigel Mongan (University
of Nottingham) and C4-2-4B by Dr Penny Ottewell (Uni-
versity of Shefﬁeld), cells were cultured as described [43].
The hOB osteoblast cell line was derived from adult femoral
head trabecular bone [44] and was provided in collaboration
with Dr Susan Anderson (University of Nottingham), hOB
cells were cultured as described [19].
Isolation and characterisation of EVs
Collection of EVs was carried out by seeding 1 × 106 cells
per 10 cm2 dish and incubating overnight. Following the
overnight incubation, cells were washed in phosphate-
buffered saline (PBS) and fresh media containing exosome-
free fetal bovine serum (#A2720801, Gibco) applied. Cells
were incubated for 48 h under standard conditions. After 48
h, the media was collected and vesicles isolated using the
exoEasy Maxi kit (#76064, Qiagen, Manchester, UK) and
gravity ﬂow chromatography (#qEV, Izon Science, Oxford,
UK) following the manufacturers’ protocols to isolate
vesicles of less than 200 nm and within the range con-
sidered to represent exosomes. EVs were characterised by
electrophoresis and Brownian motion analysis using laser
scattering microscopy (ZetaView, ParticleMetrix, Meer-
busch, Germany). Total protein was determined using the
Qubit Protein Assay Kit (#Q33211, ThermoFisher,
Loughborough, UK) and the Qubit 3.0 instrument (Ther-
moFisher). EV protein markers were assessed by immuno-
blot as subsequently described in the Protein extraction and
immunoblots section.
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Co-incubation and EV treatment of hOB cells
Co-incubation experiments were performed by seeding 3 ×
105 PCa cells into 0.4 µm tissue culture inserts (#657641,
Greiner Bio-one, Stonehouse, UK) in 3 ml media and 2 ×
105 hOB cells per well in six-well plates. Cells were incu-
bated for 24 h prior to the transfer of inserts into six-well
plates containing hOB cells. The two cell types were co-
incubated for a further 48 h prior to analysis.
To treat cells with EVs, recipient cells (hOBs) were
seeded into six-well plates at 2 × 105 cells per well. Fol-
lowing an overnight incubation, the media was replaced
with media containing exosome-free fetal bovine serum
(#A2720801, Gibco) and cells were grown for 24 h prior to
the application of isolated EVs.
RNA labelling and subsequent labelled RNA
isolation from hOB cells
5EU labelling of nascent RNAs was achieved by the
addition of 5EU to the cell culture media at a ﬁnal con-
centration of 0.4 mM for 24 h. To isolate labelled 5EU
mRNAs from recipient cells, the Click-iT Nascent RNA
Capture Kit (#C10365, ThermoFisher) was used, following
the manufacturers recommended protocol. Unlabelled con-
trols were used to determine the background level of RNA
recovery of the precipitation step.
RNAi transfection
Depletion of Dicer was achieved using Mission siRNAs
(Dicer: SASI_Hs01_00160748, si-scr: SIC001, Sigma),
modulation of miR21 was achieved using a custom-
designed siRNA or Mission miR21 mimic (HMI0371/2,
Sigma, Salisbury, UK). Cells were seeded at 3 × 104 in 24-
well plates and incubated overnight at 37 °C at 5%CO2.
Cells were subsequently transfected with 20 nM siRNA
using 1 µl Lipofectamine RNAiMAX reagent (#13778150,
ThermoFisher), or 90 nM mimic miR21 and 4.5 µl Lipo-
fectamine RNAiMAX following the manufactures recom-
mended protocol for forward transfection.
Luciferase reporter assays
Reporter constructs were created by cloning the miR21 seed
sequences into the 3’-UTR of the psiCHECK2 dual luci-
ferase reporter plasmid (#C8021, Promega, Southampton,
UK). hOB cells were seeded into a 96-well plate at a density
of 8 × 103 cells per well, and subsequently transfected with
20 ng of psiCHECK2 plasmid DNA using 0.3 µl of Fugene
HD transfection reagent (#E2311, Promega) following the
manufactures recommended protocol. Forty-eight hours
post transfection, cells were washed three times in PBS
prior to the application of EVs in exosome-free media. Cells
were lysed 72 h post- transfection using 100 µl Passive
Lysis buffer (#E1941, Promega) and the luciferase lumi-
nescence read using the Dual-Glo Luciferase Assay System
(#E2920, Promega).
Measurement of cell viability
Assessment of cell viability was made by measuring the cell
titre at the time points detailed. Cell titre was determined
using both manual haemocytometer counts (without trypan
blue) and the CellTiter-Glo assay system (#G7570, Pro-
mega) following the manufacturer’s protocol and luciferase
readings measured using a GloMax-Multi Jr Single-Tube
Multimode Reader (E6076, Promega) using the Cell-titre-
Glo default settings. Viability was determined using Real-
Time Glo MT Viability assay system (#G9711, Promega),
following all steps of the manufacturer’s protocol and
readings taken using a GloMax-Multi Jr Single-Tube Mul-
timode Reader (E6076, Promega) using the Cell-titre-Glo
default settings.
RNA extraction, quantitative PCR and RNASeq
RNA was extracted from cells using the miRNeasy miRNA
isolation mini kit (#217004, Qiagen). To quantify mRNA of
interest, cDNA synthesis and quantitative PCR (qPCR)
were conducted using the GoTaq 2-Step RT-qPCR dye-
based detection system (#A6010, Promega) and a Roche
480 Lifecycler (Roche, Sussex, UK). Quantiﬁcation of
microRNAs was achieved using the MystiCq microRNA
cDNA synthesis mix and MystiCq microRNA qPCR dye-
based assay primer system (#MIRRT, Sigma). Primers are
detailed in Supplementary Table 3. For RNAseq samples
were prepared using the Truseq small RNA library (#RS-
200-0012, Illumina, Essex, UK), Truseq Stranded RNA
library (#20020597, Illumina) and sequenced using the
NextSeq 500 High Output Run (150 cycles) for two bio-
logical replicates. Two biological replicates were sequenced
and analysis conducted using Cutadtapt, SHRiMP, SAM-
tools for trimming, mapping to GRch38 build, generating
the raw counts. Data available from the Gene Expression
Omnibus GSE117744. FunRich software was used to con-
duct enrichment analysis with Fishers exact test to generate
P values [45].
Protein extraction and immunoblots
Transfected cells were washed in PBS and lysed directly
into 4 × Laemmli buffer (#1610747, Biorad, Watford, UK).
Isolated EVs were lysed directly in 4 × Laemmli buffer
(#1610747, Biorad). Immunoblots were performed as pre-
viously described [46]. All antibodies were purchased from
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Cell Signalling (NEB, Hitchin, UK) and were used at
1:1000 dilution: Dicer (D38E7, #5362 S), Beta-Tubulin
(9F3, #2128 S), Annexin V (#8555 S), Alix (3A9, #2171 S),
CD54/I-CAM (#4915 S), EpCAM (D1B3, #2626 S).
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